These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 18988289)

  • 1. Androgen suppression therapy and prostate cancer: balancing the harms and the benefits.
    Oefelein MG
    Cancer; 2008 Dec; 113(12):3275-8. PubMed ID: 18988289
    [No Abstract]   [Full Text] [Related]  

  • 2. Side-effects of treatments for locally advanced prostate cancer.
    Gardiner RF; Nicol DL; Green HJ; Pakenham KI
    BJU Int; 2006 Jul; 98(1):229-30. PubMed ID: 16831173
    [No Abstract]   [Full Text] [Related]  

  • 3. Toward the optimal use of androgen suppression therapy in the radiotherapeutic management of prostate cancer.
    D'Amico AV
    J Clin Oncol; 2007 Jan; 25(1):8-9. PubMed ID: 17194901
    [No Abstract]   [Full Text] [Related]  

  • 4. Lifestyle intervention in men with advanced prostate cancer receiving androgen suppression therapy: a feasibility study.
    Bourke L; Doll H; Crank H; Daley A; Rosario D; Saxton JM
    Cancer Epidemiol Biomarkers Prev; 2011 Apr; 20(4):647-57. PubMed ID: 21335510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Androgen deprivation and radiation therapy.
    McKenzie MR
    Urology; 1996 Feb; 47(2):286. PubMed ID: 8607256
    [No Abstract]   [Full Text] [Related]  

  • 6. Cardiovascular risk during androgen deprivation therapy for prostate cancer.
    Jones TH
    BMJ; 2011 May; 342():d3105. PubMed ID: 21610041
    [No Abstract]   [Full Text] [Related]  

  • 7. Metabolic syndrome and prostate cancer: a review.
    Nobes JP; Langley SE; Laing RW
    Clin Oncol (R Coll Radiol); 2009 Apr; 21(3):183-91. PubMed ID: 19111451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Degarelix (firmagon) for prostate cancer.
    Med Lett Drugs Ther; 2009 Oct; 51(1323):82-3. PubMed ID: 19838145
    [No Abstract]   [Full Text] [Related]  

  • 9. "Staging the aging" when considering androgen deprivation therapy for older men with prostate cancer.
    Dale W
    J Clin Oncol; 2009 Jul; 27(21):3420-2. PubMed ID: 19506150
    [No Abstract]   [Full Text] [Related]  

  • 10. [Interest of the radiotherapy-hormonotherapy association in the treatment of the high-risk prostate cancer].
    Bolla M; Fourneret P; Descotes JL
    Bull Cancer; 2008 Dec; 95(12):1213-8. PubMed ID: 19091656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic therapeutic strategies for prostate cancer.
    Nelson WG
    Clin Adv Hematol Oncol; 2005 Aug; 3(8):619-21. PubMed ID: 16167046
    [No Abstract]   [Full Text] [Related]  

  • 12. Androgen deprivation therapy in high-risk prostate cancer.
    Buyyounouski MK
    Oncology (Williston Park); 2010 Aug; 24(9):806, 809. PubMed ID: 20923033
    [No Abstract]   [Full Text] [Related]  

  • 13. Re: Skeletal fracture associated with androgen suppression induced osteoporosis: the clinical incidence and risk factors for patients with prostate cancer.
    Miró C; De Cobelli O; Orecchia R; Sancho G; Villavicencio H; Craven-Bartle J
    J Urol; 2002 Aug; 168(2):662-3; author reply 663. PubMed ID: 12131341
    [No Abstract]   [Full Text] [Related]  

  • 14. Cardiovascular risk associated with androgen deprivation therapy.
    Leja MJ; Yeh ET
    Oncology (Williston Park); 2010 Aug; 24(9):799, 803, 806. PubMed ID: 20923032
    [No Abstract]   [Full Text] [Related]  

  • 15. Prostate cancer: new studies of combination therapy.
    Harv Mens Health Watch; 2005 Jan; 9(6):5-7. PubMed ID: 15773010
    [No Abstract]   [Full Text] [Related]  

  • 16. Twenty years of controversy surrounding combined androgen blockade for advanced prostate cancer.
    Moul JW
    Cancer; 2009 Aug; 115(15):3376-8. PubMed ID: 19484788
    [No Abstract]   [Full Text] [Related]  

  • 17. Re: Urs E. Studer, Laurence Collette, Peter Whelan, et al. Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891). Eur Urol 2008;53:941-9 and re: John Anderson. Androgen-deprivation therapy--It's all a matter of timing. Eur Urol 2008;53:869-71.
    Kirollos MM
    Eur Urol; 2009 Feb; 55(2):e40-2; author reply e45-6. PubMed ID: 18760526
    [No Abstract]   [Full Text] [Related]  

  • 18. Cardiovascular effects of androgen depletion and replacement therapy.
    Pinthus JH; Trachtenberg J; Klotz L
    Urology; 2006 Jun; 67(6):1126-32. PubMed ID: 16765164
    [No Abstract]   [Full Text] [Related]  

  • 19. Focal Therapy Gains Ground in Low-Risk Prostate Cancer.
    Schmidt C
    J Natl Cancer Inst; 2015 Sep; 107(9):. PubMed ID: 26341001
    [No Abstract]   [Full Text] [Related]  

  • 20. Colorectal Cancer: The Last Nail in the Coffin for Androgen Deprivation Therapy for Prostate Cancer?
    Balducci L; Pow-Sang JM
    Cancer Control; 2015 Apr; 22(2):259-60. PubMed ID: 26068774
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.